Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA lifts hold on NeoRx' STR (Skeletal Targeted Radiotherapy) programme:

This article was originally published in Clinica

Executive Summary

The US FDA has lifted its hold on the further development of NeoRx' Skeletal Targeted Radiotherapy (STR) product for treating multiple myeloma, a cancer of the bone marrow. The agency's decision follows NeoRx's submission of data from a dosimetry study of STR, which had been requested by the FDA. The Seattle, Washington firm said that it intended to submit a phase III study protocol before the end of the second quarter of 2003 for review by the FDA. Three-year survival data on the STR phase I/II patients is expected to become available by the end of this year.

You may also be interested in...



Pfizer And Moderna Under Pressure To Agree Vaccine Supplies For Developing Nations

As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.

FDA Releases Final Guidance For Complex ANDA Meetings

The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.

UK Government Backs Vitamin D COVID Benefits With Supplement Handout

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

Topics

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel